NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Prenetics Global Limited PRE
5 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$30.6M
▲ 40.8% vs FY2023
EPS · FY24
$-3.71
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-24.6%
Net margin · FY24
-151.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 30.6M
Revenue, FY2024 · full 5-year series below
Revenue
Net income
The company lost 151 cents on every revenue dollar this year.
Per share
USD -3.71
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-24.6%
Return on equity, FY2024
ROE
Operating margin-157.2%
Net margin-151.2%
Return on assets-19.8%
Each USD of equity lost 25 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+34.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 213.6M
total assets, end of FY2024
Total assetsUSD 213.6M
EquityUSD 170.4M
CashUSD 52.3M
Current ratio2.36×
Equity funds 80% of total assets.
History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.1
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.0
EBITDA $B
·
·
·
·
·
Income tax $B
−0.0
−0.0
−0.0
0.0
−0.0
Net income $B
−0.0
−0.1
−0.2
−0.2
−0.0
EPS, diluted $
−3.71
−5.58
−37.57
−178.81
−0.15
Dividend / sh $
·
·
·
·
·
Payout %
·
·
·
·
·
ROE %
−24.6
−28.3
·
·
·
Shares out B
0.01
0.01
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed